Sun Pharma to Acquire Organon in $11.75 Billion Deal
Indian drugmaker Sun Pharmaceutical is set to acquire US-based Organon for $11.75 billion, a move expected to significantly expand Sun Pharma's global reach and US footprint.
The Story
Analyzing sources…
Source Diversity
Source Diversity
High (63/100)Sources
Sun Pharmaceutical to Acquire Organon Valued at $11.75 Billion - WSJ
Sun Pharmaceutical to Acquire Organon Valued at $11.75 Billion WSJ
Read full article →Indian drugmaker Sun Pharma to buy U.S. firm Organon in $11.75 billion deal
To fuel its global ambitions, Sun Pharmaceutical Industries will acquire New Jersey-based Organon & Co in an all-cash deal that values the U.S. company at $11.75 billion.
Read full article →Sun Pharma to acquire Organon for $11.75bn
Read full article →Sun Pharma to acquire US-based Organon in $11.75bn deal
Indian pharmaceutical giant Sun Pharma is set to acquire US-based Organon & Co. for $11.75 billion in an all-cash deal. This landmark acquisition, one of India's largest overseas ventures, will propel Sun Pharma into the top 25 global pharma companies. The move significantly bolsters its presence in women's health and biosimilars, expanding its global reach across 150 countries.
By TOI BUSINESS DESK
Read full article →Sun Pharma to acquire Organon for $11.75 bn: How this will expand US footprint, why the timing is significant
By George Mathew
Read full article →